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Mitochondrial aldehyde dehydrogenase (ALDH2) was
reported to catalyze bioactivation of nitroglycerin (GTN),
resulting in the formation of a nitric oxide (NO) – like
species activating soluble guanylate cyclase (sGC). How-
ever, the reaction product is thought to be nitrite, which
does not activate sGC, so the link between GTN metabo-
lism and sGC activation is not clear yet.
Since we found no link between ALDH2-catalyzed GTN
metabolism and mitochondrial nitrite reduction (Kollau
A., Beretta M. & Mayer B.; unpublished), we investigated
the possibility that an activator of sGC is produced
directly in the course of ALDH2 reaction by co-incubation
of purified human ALDH2 with purified sGC in the pres-
ence of GTN. In the absence of ALDH2, GTN had no effect
on sGC activity (0.28 ± 0.07 μmol/mg/min). In the pres-
ence of 25 μg of ALDH2 there was a biphasic stimulation
of cGMP formation with an EC50 (half-maximally effec-
tive concentration) of ~1 μM GTN and a maximum at 10
μM GTN (1.66 ± 0.22 μmol/mg/min). The effect of
ALDH2 was dependent on the protein concentration,
with a linear increase from 1 to 100 μg (2.10 ± 0.23 μmol/
mg/min) and saturation between 100 and 250 μg of
ALDH2. ALDH2-dependent sGC activation was inhibited
by 1 mM chloral hydrate (41.5% of control) and by 100
μM daidzin (18.9% of control). The effect of ALDH2 on
cGMP formation was almost completely inhibited by the
NO scavenger oxy-haemoglobin, the superoxide genera-
tor flavin adenine dinucleotide, and the heme site sGC
inhibitor ODQ (0.1 mM, each).
The cytosolic ALDH isoform (ALDH1) also metabolized
GTN to 1,2- and 1,3-GDN (dinitroglycerin) and triggered
sGC activation. In line with the about 1,000-fold lower
substrate affinity of ALDH1, significantly higher GTN con-
centrations were required for sGC activation. There was a
linear increase in cGMP formation by sGC co-incubated
with 50 μg of ALDH1 and 10 μM to 1 mM GTN. At the
highest GTN concentration tested (1 mM), sGC activity
was 4.25 ± 0.15 μmol/mg/min. As observed with ALDH2-
mediated sGC activation, the response to ALDH1 was
dependent on the protein concentration with a linear
increase from 5 to 100 μg ALDH1. The effect of ALDH1 on
cGMP formation was inhibited by 1 mM chloral hydrate
(57% of control) but not by 100 μM daidzin.
These results suggest that both ALDH1 and ALDH2 cata-
lyze GTN bioactivation by direct formation of NO or a
NO-like activator of sGC.
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